Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: Results from the placebo-controlled portion of a phase II, randomized, double-blind study

被引：0

作者：

Kimball, A. ^{[1
]}

Jemec, G. ^{[2
]}

Okun, M. ^{[3
]}

Gu, Y. ^{[3
]}

机构：

[1] Harvard Univ, Sch Med, Boston, MA USA

[2] Roskilde Hosp, Roskilde, Denmark

[3] Abbott Labs, Abbott Pk, IL 60064 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2011年 / 64卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：AB155 / AB155

页数：1

共 50 条

[1] Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: results from the placebo-controlled portion of a phase II, randomized, double-blind study
Kimball, A. B.
Jemec, G.
Gu, Y.
Okun, M.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 : 6 - 6
[2] Efficacy and safety of adalimumab treatment in women with moderate to severe hidradenitis suppurativa: Analysis from the placebo-controlled portion of a phase II, randomized, double-blind study
Gottlieb, Alice B.
Menter, Alan
Teixeira, Henrique D.
Belknap, Kimberly R.
Gu, Yihua
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB49 - AB49
[3] Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study
Gottlieb, Alice
Menter, Alan
Armstrong, April
Ocampo, Christopher
Gu, Yihua
Teixeira, Henrique D.
[J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (10) : 1192 - 1196
[4] Adalimumab Treatment in Women with Moderate to Severe Hidradenitis Suppurativa Using a Novel Endpoint, HiSCR (Hidradenitis Suppurativa Clinical Response): Analysis from the Placebo-Controlled Portion of a Phase II, Randomized, Double-Blind Study.
Gottlieb, Alice
Menter, Alan
Armstrong, April
Cui, Na
Yamaguchi, Yuji
[J]. REPRODUCTIVE SCIENCES, 2014, 21 (03) : 220A - 221A
[5] A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
Miller, I.
Lynggaard, C. D.
Lophaven, S.
Zachariae, C.
Dufour, D. N.
Jemec, G. B. E.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (02) : 391 - 398
[6] Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from PIONEER II, a phase 3, randomized, placebo-controlled trial
Jemec, Gregor
Gottlieb, Alice
Forman, Seth
Giamarellos-Bourboulis, Evangelos
Reguiai, Ziad
Gu, Yihua
Okun, Martin
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB45 - AB45
[7] Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial
Glatt, Sophie
Jemec, Gregor B. E.
Forman, Seth
Sayed, Christopher
Schmieder, George
Weisman, Jamie
Rolleri, Robert
Seegobin, Seth
Baeten, Dominique
Ionescu, Lucian
Zouboulis, Christos C.
Shaw, Stevan
[J]. JAMA DERMATOLOGY, 2021, 157 (11) : 1279 - 1288
[8] Adalimumab in conjunction with surgery in patients with moderate to severe Hidradenitis Suppurativa: Study design and baseline results from a phase 4, double-blind, randomized, placebo-controlled study
Bechara, F.
Horvath, B.
Jemec, G.
Podda, M.
Prens, E.
Zouboulis, C.
Geng, Z.
Capriles, C. Rodriguez
[J]. EXPERIMENTAL DERMATOLOGY, 2018, 27 : 14 - 14
[9] Adalimumab in conjunction with surgery in patients with moderate to severe hidradenitis suppurativa: baseline characteristics from a phase 4, double-blind, randomized, placebo-controlled study
Bechara, Falk G.
Horvath, Barbara
Jemec, Gregor B. E.
Podda, Maurizio
Prens, Errol P.
Geng, Ziqian
Jean, Christine
Zouboulis, Christos C.
[J]. EXPERIMENTAL DERMATOLOGY, 2020, 29 : 38 - 38
[10] Efficacy and safety of Adalimumab in patients with moderate to severe hidradenitis suppurativa: results from PIONEER II, a phase 3 randomised placebo-controlled trial
Herra, L. Escudero
Jemec, G. B. E.
Gottlieb, A.
Forman, S.
Giamarellos-Bourboulis, E. J.
Reguiai, Z.
Gu, Y.
Okun, M. M.
[J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 34 - 35

← 1 2 3 4 5 →